Author

Simon J. Ogrodnik

Observed names: Ogrodnik, Simon, Ogrodnik, Simon J., SJ Ogrodnik, Simon John Ogrodnik, Simon Ogrodnik

Institution: German Cancer Research Center

Observed institutions: German Cancer Research Center, Heidelberg University, University Hospital Heidelberg, National Center for Tumor Diseases, German Center for Lung Research, Deutsches Konsortium für Translationale Krebsforschung

ORCID: 0000-0002-8589-4116

Observed ORCID: 0000-0002-8589-4116

OpenAlex ID: A5035449648

Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA

2020 · Steffen Dietz, Petros Christopoulos, et al. · EBioMedicine · 48

Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis

2021 · Arlou Kristina Angeles, Petros Christopoulos, et al. · npj Precision Oncology · 41

Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival

2019 · Petros Christopoulos, Steffen Dietz, et al. · Cancers · 39

Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in KLC1–ALK-rearranged lung cancer

2019 · Steffen Dietz, Petros Christopoulos, et al. · Molecular Case Studies · 23

Low-coverage whole genome sequencing of cell-free DNA to predict and track immunotherapy response in advanced non-small cell lung cancer

2025 · Florian Janke, Mateo Gasser, et al. · Journal of Experimental & Clinical Cancer Research · 17

Early circulating tumor DNA changes predict outcomes in head and neck cancer patients under re‐radiotherapy

2024 · Florian Janke, Florian Stritzke, et al. · International Journal of Cancer · 14

Etiology-independent activation of the LTβ-LTβR-RELB axis drives aggressiveness and predicts poor prognosis in HCC

2023 · Anna-Lena Scherr, Luisa Nader, et al. · Hepatology · 12

Abstract 1803: Dynamic copy number changes and de novo generation of extrachromosomal DNA modulate therapy resistance.

2026 · Tim Vorberg, Manuel Reitberger, et al. · Cancer Research

Abstract A21: Longitudinal analysis of cell-free DNA for therapy monitoring of ALK-positive non-small cell lung cancer

2020 · Steffen Dietz, Petros Christopoulos, et al. · Clinical Cancer Research

TP53 status conversion defines an unfavourable patient subset with inferior overall survival in ALK+ lung adenocarcinoma

2019 · P Christopoulos, S Dietz, et al. · Pneumologie

Works count: 14

Citation count: 194

H-index: 7

I10-index: 7